News 
Market Data 
Discover
Vaz
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OXIS NEWS...>>>The New England Journal of Medicine is One of the MOST respected Medical Journals...
OXIS International Oxidative Stress Blood Test May Predict Heart Attack
Tuesday October 28, 8:11 am ET
Assay Used In Lead New England Journal of Medicine Study
http://biz.yahoo.com/bw/031028/285353_1.html
PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 28, 2003--An article, published by scientists from the Cleveland Clinic Foundation in the October 23, 2003 issue of the New England Journal of Medicine, reports that an assay developed by OXIS International, Inc. (OTCBB:OXIS - News; Noveau Marche:OXIS) enabled the prediction of early risk of cardiovascular diseases. A single oxidative-stress measurement of myeloperoxidase (MPO) levels in blood plasma, using OXIS-MPO Assay, was essential to independently predicting serious cardiac events, including myocardial infarction and death, in the 604 patients studied.
ADVERTISEMENT
Hailed as "a new era of heart disease detection" by USA Today, the blood test could provide the ability to diagnose an imminent heart attack. More than 500,000 Americans will die this year of cardiovascular disease and more than two million people will suffer a new or recurrent chest pain or heart attack. In 2003, the total economic cost of cardiovascular disease is estimated at $129.9 billion by the Heart Disease and Stroke Statistics, 2003 Update. Early detection of cardiovascular disease may not only contribute to health and wellness, but also may reduce skyrocketing health-care costs.
The OXIS-MPO Oxidative Stress kit played a significant role in this advance in the field of cardiovascular disease. Currently used biomarkers for myocardial infarction present significant limitations in predictive quality due to variability of patient population, the range for abnormal test results, and other factors. In contrast, blood plasma MPO levels, as measured by the OXIS-MPO Oxidative Stress kit with OXIS' own monoclonal antibody, were a better predictor of patients at risk for cardiac events before they occurred, according to the New England Journal of Medicine report.
Oxidative stress occurs as a result of an imbalance between damaging free-radicals and related molecules and their inactivation by antioxidants. Oxidative stress can cause tissue injury by triggering cell death or inciting a tissue-damaging inflammatory response. Detection of these destructive activities may be demonstrated by accurately measuring changes in MPO levels, an indicator of oxidative-stress levels.
"The OXIS-MPO Oxidative Stress kit is currently in use by major universities and research institutions throughout the world," stated Ray R. Rogers, CEO of OXIS. "OXIS will accelerate the availability of its MPO research kit to meet the expanding demand of the research community, and to further support validation of these initial results."
OXIS International, headquartered in Portland, Oregon, focuses on developing technologies and products to research, diagnose, treat and prevent diseases associated with damage from free radical and reactive oxygen species -- diseases of oxidative stress. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress and, through its Health Products division, develops, manufactures and markets products and technologies to diagnose and treat diseases caused by oxidative stress.
Statements in this release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, any statements regarding beliefs, plans, estimates, projections, expectations, goals or intentions regarding the future. Forward-looking statements in this release include statements regarding the OXIS oxidative blood test's ability to predict a heart attack; the number of people who will die of heart attacks; the number of people who will suffer chest pain or a heart attack; that early detection of cardiovascular disease may reduce health-care costs and that there will be expanding demand for the OXIS-MPO research kit. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties such as unforeseen difficulties related to the company's MPO Oxidative Stress kit and other diagnostic products; decreases in the rate of spending by the company's customers; results from further studies or tests concerning the correlation of MPO to the likelihood of a heart attack; the development by the company's competitors of new competing products; and other risks indicated in the company's filings with the Securities and Exchange Commission. It is important to note that actual outcomes could differ materially from those in such forward-looking statements. Readers should also refer to the documents filed by the company with the Securities and Exchange Commission, specifically the annual report on Form 10-KSB for the year ended December 31, 2002, filed with the Securities and Exchange Commission on March 31, 2003.
--------------------------------------------------------------------------------
Contact:
Investor Relations:
Investor Awareness, Inc.
Tony Schor/Paul Arndt, 847-945-2222
info@investorawareness.com
Media Relations:
Obidicut LLC
Will Anderson, 503-452-7621
will@obidicut.net
HMP...
Horizon Medical Products Earnings Conference Call (Q3 2003)
Scheduled to start Tue, Oct 28, 2003, 2:00 pm Eastern
Horizon Medical Products, Inc. Receives FDA Clearance For Its Vortex MP Port System
http://biz.yahoo.com/bw/030930/305643_1.html
Income Statement
http://finance.yahoo.com/q/is?s=hmp
HOLL...
MovieTickets.com Expands Theater Partnerships To United Kingdom
http://biz.yahoo.com/prnews/030909/fltu010a_1.html
Income Statement
http://finance.yahoo.com/q/is?s=holl
Market Cap (intraday): 36.62M
Revenue (ttm): 58.24M
Book Value Per Share (mrq): 1.79
Shares Outstanding: 21.04M
Float: 19.40M
VMII...I'll be watching this one...>>>
Voice Mobility adds support for Linux
http://biz.yahoo.com/prnews/031008/va070_1.html
Voice Mobility announces agreement with Avaya
http://biz.yahoo.com/cnw/030915/voice_agreemnt_avaya_2.html
Voice Mobility arranges private placement financing
http://biz.yahoo.com/prnews/030911/va254_1.html
MULTEX ABRIDGED BUSINESS SUMMARY
Voice Mobility International, Inc. is engaged in the development and sales and marketing of unified voice messaging software through its wholly owned operating subsidiaries, Voice Mobility Inc. and Voice Mobility (US) Inc. The Company's enhanced messaging software suite allows for legacy voice-mail replacement and incremental offerings such as real-time call connect, voice-mail to e-mail and fax to e-mail services. These unified communication services are facilitated by the creation of a single personal digital mailbox that can receive any type of communication regardless of its incoming format or medium. The Company's enhanced messaging software suite is designed to function on industry-standard commodity hardware such as Intel processor-based servers. Its enhanced messaging software suite also uses communication boards from NMS Communications
But Buyer beware
4190 Lougheed Highway, Suite 100
Burnaby, BC V5C 6
Phone: (604) 482-0000
Fax: (604) 482-0715
Email: investors@voicemobility.com
Web Site: http://www.voicemobility.com/home.html
AI
